NCT03806309
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03806309
Title OSE2101+FOLFIRI, or FOLFIRI Maintenance After FOLFIRINOX-based Induction Therapy in Advanced or Metastatic PDAC (TEDOPAM)
Acronym TEDOPAM
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors GERCOR - Multidisciplinary Oncology Cooperative Group
Indications
Therapies
Age Groups: adult | senior
Covered Countries FRA

Facility Status City State Zip Country Details
Clinique de l'Europe Amiens France Details
Hôpital Sud CHU Amiens Amiens France Details
CH Beauvais Beauvais France Details
CHRU Jean Minjoz Besançon France Details
Clinique Tivoli Ducos Bordeaux France Details
CHU Morvan Brest France Details
GHPSO Site de Creil Creil France Details
Hôpital Henri Mondor Créteil France Details
Centre Georges François Leclerc Dijon France Details
CHU Dijon Dijon France Details
CHRU Lille Lille France Details
centre Léon Bérard Lyon France Details
Hôpital Edouard Herriot Lyon France Details
Hôpital la Croix Rousse Lyon France Details
Hôpital Lyon Sud Hospices Civils de Lyon Lyon France Details
Hôpital Privé Jean Mermoz Lyon France Details
Hôpital Européen Marseille France Details
Institut Paoli Calmette Marseille France Details
Hôpital Pitié Salpêtrière Paris France Details
Hôpital Saint Antoine Paris France Details
Institut Mutualiste Montsouris Paris France Details
CHU Poitiers Poitiers France Details
CHU Robert Debré Reims France Details
Institut Curie Saint-Cloud France Details
Centre Paul Strauss Strasbourg France Details
Clinique Pasteur Toulouse France Details
Hôpital TROUSSEAU Tours France Details
Insitut de Cancérologie de Lorraine Vandœuvre-lès-Nancy France Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field